Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance

The Journal of Headache and Pain 2021 May 18;22(1):39. doi: 10.1186/s10194-021-01252-4. Simona Sacco, Christian Lampl, Antoinette Maassen van den Brink, Valeria Caponnetto, Mark Braschinsky, Anne Ducros, Patrick Little, Patricia Pozo-Rosich, Uwe Reuter, Elena Ruiz de la Torre, Margarita Sanchez Del

Severe migraine and its control: A proposal for definitions and consequences for care

Revue Neurologique 2021 Mar 30; doi: 10.1016/j.neurol.2020.11.012.  Anne Donnet  , Anne Ducros  , Françoise Radat  , Bashar Allaf  , Isabelle Chouette  , Michel Lanteri-Minet Abstract Currently many patients with severe migraine do not receive appropriate treatment and are never referred to specialist headache centres.

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society

Cephalalgia 2021 Jan 20;333102421989247 doi: 10.1177/0333102421989247. Online ahead of print. Hans Christoph Diener , Messoud Ashina, Isabelle Durand-Zaleski, Tobias Kurth, Michel Lantéri-Minet, Richard B Lipton, Daniel A Ollendorf, Patricia Pozo-Rosich, Cristina Tassorelli, Gisela Terwindt Abstract The Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology

Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful: results from the LIBERTY study

Journal of neurology, neurosurgery, and psychiatry 2021 Jan 5;jnnp-2020-324396  doi: 10.1136/jnnp-2020-324396. Online ahead of print. Michel Lanteri-Minet, Peter J Goadsby, Uwe Reuter, Shihua Wen, Peggy Hours-Zesiger, Michel D Ferrari, Jan Klatt Objective: To evaluate the effect of erenumab on patient-reported, functional outcomes in patients with episodic

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

THE LANCET Neurology Volume 19, ISSUE 10, P814-825, October 01, 2020 Wim M Mulleners, Byung-Kun Kim, Miguel J A Láinez, Michel Lanteri-Minet, Patricia Pozo-Rosich, Shufang Wang, Antje Tockhorn-Heidenreich, Sheena K Aurora, Russell M Nichols, Laura Yunes-Medina, Holland C Detke. Background Many patients who require migraine preventive treatment have not been

Étude de phase III, contrôlée, randomisée, de supériorité de galcanézumab versus placebo, chez les patients atteints de migraine difficile à traiter : résultats de l’étude CONQUER

Vol 176 – N° S – septembre 2020 P. S2-S148 © Elsevier Masson SAS Journées de Neurologie de Langue Française 2020 Wim M Mulleners, Byungkun Kim , Miguel Ja Láinez, Michel Lanteri-Minet, , Sheena K Aurora, Russell M Nichols ,

Migraine and Two-Pore-Domain Potassium Channels

The Neuroscientist. 2020 Jul 27;1073858420940949. doi: 10.1177/1073858420940949. Online ahead of print. Migraine and Two-Pore-Domain Potassium Channels Clément Verkest, Stephanie Häfner, Pablo Ávalos Prado, Anne Baron, Guillaume Sandoz PMID: 32715910 DOI: 10.1177/1073858420940949 Abstract Migraine is a common, disabling neurological disorder with a genetic, environmental, and

Two-pore-domain potassium channels and molecular mechanisms underlying migraine

Biologie Aujourd’hui 2019;213(1-2):51-57. doi: 10.1051/jbio/2019020. Epub 2019 Jul 5. [Two-pore-domain potassium channels and molecular mechanisms underlying migraine] Perrine Royal, Pablo Ávalos Prado, Brigitte Wdziekonski, Guillaume Sandoz PMID: 31274103 DOI: 10.1051/jbio/2019020 Abstract Migraine is a common, disabling neurological disorder with genetic, environmental and hormonal